InPractice:

Clinical Insights

  • Synthetic Stimulants

    Synthetic Stimulants

    Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit drugs; however, they…

  • Nitazene Analogs

    Nitazene Analogs

    Nitazene analogs are a subclass of designer opioids that are structurally different from opioids but attach to the same mu-opioid receptor.1 This Novel…

  • Designer Benzodiazepines

    Designer Benzodiazepines

    Designer benzodiazepines (DZBDs) represent a major public health issue and their prevalence has increased substantially over the last decade.1 Slight alterations…

  • What Did My Patient Actually Take? An Overview of Alcohol Results

    What Did My Patient Actually Take? An Overview of Alcohol Results

    According to the National Survey on Drug Use and Health conducted in 2015, 86.4% of people over the age of 18 reported drinking alcohol at some point in…

  • Synthetic Cannabinoids

    Synthetic Cannabinoids

    Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of prescription or illicit drugs that are…

  • Polysubstance Use: Fentanyl and Stimulants

    Polysubstance Use: Fentanyl and Stimulants

    The United States is in an overdose epidemic, with the CDC estimating that 106,699 individuals died of a drug-involved overdose in 2021 alone. Most deaths…

  • Spotlight on Potential Interactions Involving Behavioral Health & Substance Use Disorder Medications

    Spotlight on Potential Interactions Involving Behavioral Health & Substance Use Disorder Medications

    Drug-drug and drug-food interactions (DDIs) contribute to adverse drug events (ADEs) which can range in severity from mild effects to life-threatening.…